& The Motley Fool
Hello, 360!
We’d like to share some of our top market movers today. Stay ahead as the most prepared trader on the Street!
Reminder:
Get JW’s next FOUR picks for just $29.
Offer Expires in Just…
 |
FOCUS LIST🔎
TRAW – Increased over 100% in pre-market after announcing advancements in Tivoxavir Marboxil for H5N1 Bird Flu development.
RAPT – Surged over 40% in pre-market following the disclosure of an exclusive license agreement with Shanghai Jemincare Pharmaceutical for a novel long-acting anti-IgE antibody.
PRZO – Gained over 20% in pre-market after revealing a significant Australian order for drone safety systems, affirming industry leadership.
*Sponsored by CompareCredit
Two Cards Offering 0% Interest Until 2026
Struggling to reduce your credit card balance with most payments going toward interest? Avoid interest charges for up to 18 months with these cards.
Discover More
HOTLIST🔥
TRAW – Increased over 100% in pre-market after announcing progress on Tivoxavir Marboxil for H5N1 Bird Flu
Traws Pharma Inc. (TRAW) is a clinical-stage biopharmaceutical company dedicated to developing small molecule oral therapy candidates for respiratory viral diseases and cancer.
In the pre-market this morning, they announced advancements in their investigational therapy, Tivoxavir Marboxil, intended for one-dose treatment of H5N1 bird flu.
Key Highlights:
Investigational agent targeting treatment or prevention of H5N1 Bird Flu.
Phase 1 dosing completed in healthy volunteers.
Potent inhibition of drug-resistant and bird flu viruses in vitro.
In vivo mice studies confirmed potent protection and reduced virus replication in lungs infected by H5N1 from an infected dairy worker.
Shares of
TRAW
experienced over 100% gains in the pre-market following this announcement.
The $9.70 level acted as support in pre-market, which is crucial to monitor.
Above it, targets include $10.70, $12.20, $13.50, and the pre-market high at $15.89.
Below $9.70, targets to watch for declines are $9, $8, $7.50, $6, and a gap fill at $5.02.
RAPT – Surged over 40% in pre-market after an exclusive licensing deal with Shanghai Jemincare Pharmaceutical for a novel anti-IgE antibody
RAPT Therapeutics Inc. (RAPT) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases in the U.S.
In pre-market this morning, they announced an exclusive license agreement with Shanghai Jemincare Pharmaceutical for JYB1904 (RAPT designation RPT904), a half-life extended anti-IgE monoclonal antibody in clinical-stage development.
Transaction Highlights:
– RAPT obtains worldwide rights excluding China.
– Jemincare receives a $35 million upfront payment plus up to $672.5 million in milestone payments and royalties on future sales.
– Jemincare is conducting Phase 2 trials for asthma and chronic spontaneous urticaria in China.
Shares of
RAPT
traded up over 40% in pre-market following this announcement.
The $1.40 level served as resistance during pre-market trading and should be closely monitored.
Above $1.40, potential upside targets are $1.60, $1.75, and the pre-market high at $1.97.
If it drops below $1.40, downside targets include $1.26, $1.16, $1, and a gap fill at $0.8254.
*Sponsored by The Motley Fool
Investment in Smart Technology
Referred to as “the rocket fuel of AI” by Wired, this innovation is creating significant buzz on Wall Street. With projections reaching $80 trillion—equivalent to 41 Amazons—the possibilities are enormous. Sharp investors are presented with an opportunity to channel funds into technology destined for market leadership. Access the full report through The Motley Fool for more insights.
Uncover the secrets to future tech advancements today.
PRZO – Up over 20% in pre-market after confirming a key Australian order for drone safety systems, reinforcing industry leadership
ParaZero Technologies Ltd. (PRZO) is an aerospace firm that designs, develops, manufactures, distributes, and sells autonomous safety systems for commercial drones across the U.S., Israel, Canada, Europe, and globally.
This morning, they released a press statement indicating they had secured an order for their SafeAir™ systems from a significant drone technology distributor in Australia.
This order highlights ParaZero’s rapid growth within the Australian drone market, driven by recent regulatory approvals and strategic collaborations. As drone usage rises in various industries, ParaZero’s sophisticated solutions illustrate its dedication to setting and advancing drone safety standards, enabling operators to achieve top-level safety benchmarks while promoting innovation.
Shares of PRZO surged over 20% in the pre-market as a result of the press release.
The $1.93 price point acted as support in pre-market trading and should be kept an eye on.
Targets for potential growth above this are $2.05, $2.20, $2.30, and the pre-market peak at $2.36. Following that, targets include $2.44 and $2.77.
If it falls below $1.93, be mindful of a gap to fill at $1.76, with further support at $1.53.
MARKET NEWS 📰
DISCLAIMER: To fully understand any services offered by Ragingbull.com, LLC (“RagingBull”), please review our complete disclaimer at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. Any service offered by RagingBull is strictly for educational and informational purposes, and should NOT be interpreted as a securities-related offer or solicitation, nor should it be relied upon as personalized investment advice. RagingBull firmly advises consulting a licensed professional before making any investment choice.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull services may include information about historical trading performance of RagingBull proprietors or employees, or testimonials from non-employees indicating profitability that are believed to be accurate based on the declarations of those giving the testimonial voluntarily. Nevertheless, subscribers’ trading outcomes have not been tracked or authenticated, and past performance does not guarantee future results; thus, the results illustrated in this material are NOT TYPICAL. Actual outcomes may vary significantly depending on a variety of factors including experience, skills, risk management practices, market factors, and the amount of investment capital employed. Investing in securities is speculative and possesses substantial risk; you could lose a portion, all, or potentially more than your initial investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor its ownership or employees are registered as a securities broker-dealer, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory entity. Employees, owners, and other service providers of https://ragingbull.com or RagingBull.com LLC are compensated fully or partially based on commissions tied to sales of services to subscribers.
RagingBull.com, LLC may recover legal fees, costs, and expenses. Should any dispute arise from dealings with RagingBull.com, LLC and/or its related parties, or should any litigation be required to enforce or interpret these Terms of Service, RagingBull.com, LLC will be entitled to recover legal fees, costs, and expenses in addition to any other entitlements.
*Sponsored Content: If you make a purchase through any link in this email apart from RagingBull services, you should assume that we have an affiliate relationship with the provider of the product or service that you acquire, and that we will be compensated in some manner. We suggest conducting your own independent research before making any purchases. While we believe in the companies with whom we have affiliate relationships, please don’t spend any funds on these products or services unless you are convinced they will assist you in achieving your objectives.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not received any direct or indirect payment from any issuer of any security mentioned in these services except from advertisers in this email possibly. However, Ragingbull.com, LLC, its proprietors, and employees may buy, sell, or maintain long or short positions in securities of the entities discussed in this communication.
